Physician profile
David Schulman
NPI 1679553754
$6,383.27
in general payments reported to CMS, 2019-2025
15 companies · $776 in 2025
The $776 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $754 · 2021: $810 · 2022: $1,039 · 2023: $1,073 · 2024: $889 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,462 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,461.84 |
| Education | $275.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $5,302.22 | 2019-2025 | Clindacin Etz, Neuac, Neo-Synalar |
| Janssen Biotech, INC. | $261.98 | 2023-2024 | Tremfya |
| Galderma Laboratories, L.P. | $167.40 | 2019 | |
| Lilly USA, LLC | $161.65 | 2019-2024 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $120.57 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $108.54 | 2022-2025 | |
| Abbvie INC. | $60.58 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $53.62 | 2024-2025 | Sotyktu |
| Ani Pharmaceuticals, INC. | $40.77 | 2023 | Veregen |
| Organon LLC | $29.87 | 2025 | Vtama |
| Dermira, INC. | $26.66 | 2020 | |
| Sebela Pharmaceuticals INC. | $20.06 | 2022 | |
| Dermavant Sciences, INC. | $14.00 | 2023 | Vtama |
| Epi Health, LLC | $12.94 | 2022 | |
| Journey Medical Corporation | $2.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.